Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (Brilliance)

A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (PM)

Study Overview

• Status: Completed
• Conditions: Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
• Intervention / Treatment: Drug: Ranibizumab 0.5mg; Drug: Ranibizumab 0.5 mg; Drug: Verteporfin PDT

Detailed Description

This was a phase III, multi-center, randomized, double-masked, active-controlled study comparing 0.5 mg ranibizumab vs. vPDT therapy. The study included 15 scheduled visits over 12 months, and there were to be two additional visits (2a, 3a) for subset of patients in whom PK analysis were performed.

There were 3 periods in this study: Screening period-from Day -14 to Baseline; Treatment period-from Baseline to Month 11; Follow-up period-from Month 11 to Month 12 Patients entered the 11 months Treatment period at Visit 2 (Day 1) if eligibility criteria were met and were randomized in three treatment groups Group I ranibizumab 0.5 mg driven by VA stability criteria or Group II ranibizumab 0.5 mg driven by disease activity criteria or Group III vPDT (randomization ratio of 2:2:1) and received first treatment of either a ranibizumab injection and sham vPDT or sham injection and active vPDT and will return to the clinical center within 7 days to undergo safety assessments as well as assessments of the effect of treatment by the evaluating investigator. The following visits were performed at one month intervals starting at Visit 4 and continuing through Visit 14. At all monthly visits (at/from Month 2 for group I, at/from Month 1 for group II and at/from Month 3 for group III) the decision for treatment were made by the evaluating investigator based on the VA stability criteria and on the disease activity criteria. At Month 3 (visit 6) and at all following monthly visits for all three groups one of the three options can recommended by evaluating investigator: a) ranibizumab 0.5 mg, b) ranibizumab 0.5 mg + vPDT; c) vPDT. The treating investigator were then perform treatment based on randomization and masking requirements.

At each monthly visit, patients had a safety evaluation by the evaluating investigator prior to study treatment, consisting of visual acuity measurements, ophthalmic examinations and evaluation of adverse events and vital signs. Routine hematology, chemistry, and urinalysis profiles were obtained at Visit 6, 9 and 12 (Month 3, 6 and 9). At Month 12 several procedures and assessments were performed which are required at study completion visit.

• Study Type: Interventional
• Enrollment (Actual): 457
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Beijing, China, 100730
    • Novartis Investigative Site
  • Beijing, China, 100034
    • Novartis Investigative Site
  • Beijing, China, 100176
    • Novartis Investigative Site
  • Chongqing, China, 400038
    • Novartis Investigative Site
  • Shanghai, China, 200080
    • Novartis Investigative Site
  • Shanghai, China
    • Novartis Investigative Site
  • Shanghai, China, 200092
    • Novartis Investigative Site
  • Beijing
    • Beijing, Beijing, China, 100730
      • Novartis Investigative Site
    • Beijing, Beijing, China, 100191
      • Novartis Investigative Site
  • Chongqing
    • Chongqing, Chongqing, China, 400042
      • Novartis Investigative Site
  • Guangdong
    • Shantou, Guangdong, China, 515041
      • Novartis Investigative Site
  • Heilongjiang
    • Harbin, Heilongjiang, China, 150001
      • Novartis Investigative Site
  • Hubei
    • Wuhan, Hubei, China, 430060
      • Novartis Investigative Site
    • Wuhan, Hubei, China, 430070
      • Novartis Investigative Site
  • Hunan
    • Changsha, Hunan, China, 410008
      • Novartis Investigative Site
    • Changsha, Hunan, China, 410011
      • Novartis Investigative Site
  • Jiangsu
    • Nanjing, Jiangsu, China, 210029
      • Novartis Investigative Site
    • Nanjing, Jiangsu, China, 210006
      • Novartis Investigative Site
    • Wu XI, Jiangsu, China, 214023
      • Novartis Investigative Site
  • Jiangxi
    • Nanchang, Jiangxi, China, 330006
      • Novartis Investigative Site
  • Shandong
    • Qingdao, Shandong, China, 266011
      • Novartis Investigative Site
  • Shanxi
    • Xi'an, Shanxi, China, 710032
      • Novartis Investigative Site
  • Sichuan
    • Chengdu, Sichuan, China, 610041
      • Novartis Investigative Site
  • Tianjin
    • Tianjin, Tianjin, China, 300020
      • Novartis Investigative Site
    • Tianjin, Tianjin, China, 300070
      • Novartis Investigative Site
  • Zhejiang
    • Hangzhou, Zhejiang, China, 310009
      • Novartis Investigative Site
    • Wenzhou, Zhejiang, China, 325027
      • Novartis Investigative Site
• Hong Kong
  • Hongkong, Hong Kong
    • Novartis Investigative Site
• India
  • Angamaly, India, 683572
    • Novartis Investigative Site
  • New Delhi, India, 110029
    • Novartis Investigative Site
  • Haryana
    • Chandigarh, Haryana, India, 160 030
      • Novartis Investigative Site
  • Karnataka
    • Bangalore, Karnataka, India, 560 010
      • Novartis Investigative Site
  • Kerala
    • Vanchiyoor, Kerala, India, 695035
      • Novartis Investigative Site
  • Orissa
    • Bhubaneswar, Orissa, India, 751024
      • Novartis Investigative Site
  • Tamil Nadu
    • Chennai, Tamil Nadu, India, 600006
      • Novartis Investigative Site
    • Chennai, Tamil Nadu, India, 600 015
      • Novartis Investigative Site
    • Coimbatore, Tamil Nadu, India, 641 014
      • Novartis Investigative Site
  • Telangana
    • Hyderabad, Telangana, India, 500 034
      • Novartis Investigative Site
• Korea, Republic of
  • Pusan, Korea, Republic of, 614 735
    • Novartis Investigative Site
  • Seoul, Korea, Republic of, 03722
    • Novartis Investigative Site
  • Seoul, Korea, Republic of, 02841
    • Novartis Investigative Site
• Philippines
  • Metro Manila
    • Manila, Metro Manila, Philippines, 1000
      • Novartis Investigative Site
    • Manila, Metro Manila, Philippines, 1008
      • Novartis Investigative Site
• Thailand
  • Bangkok, Thailand, 10700
    • Novartis Investigative Site
  • Chiang Mai, Thailand, 50200
    • Novartis Investigative Site
  • Nakornphathom, Thailand, 73210
    • Novartis Investigative Site
  • THA
    • Khon Kaen, THA, Thailand, 40002
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Visual impairment due to CNV secondary to PM.
• Best corrected visual acuity in the study eye > 24 and < 78 ETDRS letters.
• High myopia (> -6D),
• anterio-posterior elongation > 26 mm; posterior changes compatible with the pathologic myopia.
• Either CNV locations in the study eye: subfoveal, juxtafoveal, extrafoveal.

Exclusion Criteria:

• Some preexisting eye disorders or systemic diseases;-Blood pressure > 150/90 mmHg
• Prior focal/grid laser to the macular area -History of treatment with any anti-VEGF or verteporfin PDT in the study eye
• Intravitreal treatment with corticosteroids or intraocular surgery within last 3 months in the study eye

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Group I; 0.5 mg ranibizumab driven by visual acuity stability criteria	Drug: Ranibizumab 0.5mg; 0.5 mg ranibizumab (intravitreal injections); Other Names: Lucentis
EXPERIMENTAL: Group II; 0.5 mg ranibizumab driven by disease activity criteria	Drug: Ranibizumab 0.5 mg; 0.5 mg ranibizumab (intravitreal injections); Other Names: Lucentis
ACTIVE_COMPARATOR: Group III; verteporfin PDT	Drug: Verteporfin PDT; Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application; Other Names: Visudyne

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3	Best corrected visual acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) charts testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.	From Baseline to Month 3

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 6	Best corrected visual acuity (BCVA) was tested using the early treatment diabetic retinopathy study (ETDRS) VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF. Between treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 6.	From Baseline to Month 6
The Average Change in BCVA Score From Baseline to Month 1 Through Month 12	Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF. Between treatment comparison of 0.5 mg ranibizumab intravitreal injections driven by disease activity re-treatment criteria (Group II) versus 0.5 mg ranibizumab intravitreal injections driven by visual acuity stability criteria (Group I) based on the average BCVA change from Baseline to Month 1 through Month 12	From Baseline to Month 12
Mean Change From Baseline in Visual Acuity Over Time	Best corrected visual acuity (BCVA) was tested using the ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.	Change from baseline at months 3, 6, and 12
Categorized BCVA Changes at Months 3, 6 and 12 Compared With Baseline for the Study Eye	ETDRS VA testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts. The overall BCVA score was calculated using the BCVA worksheet, which was kept in the source data and the score was recorded in the eCRF.	From Baseline to Month 12
Mean Change From Baseline Over Time in Central Sub-field Thickness (CSFT)	Central sub-field thickness (CSFT) is a variable assessed via Optical Coherence Tomography (OCT). OCT was performed prior to any study drug administration to assess presence of intra, subretinal fluid, or increase of CSFT.	Baseline, Month 3, Month 6, and Month 12
Number of Patients With CNV Leakage (Center Involvement) in the Study Eye at Baseline and Month 12	CNV leakage is assessed via fluorescein angiography (center involvement) category: definite, questionable, absent, can't grade, and missing.	From Baseline until Month 12
NEI-VFQ-25 - Change From Baseline to Month 3, 6 and 12	The VFQ-25 consists of 25 vision related questions across 11 vision related subscales, including general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision and peripheral vision, and a general health rating. Items are converted to a 0-100 scale on each subscale and for the composite score where higher scores represents better functioning.	Change from baseline at month 3, 6 and 12
Number of Ranibizumab Injections Received in the Study Eye for the Ranibizumab Groups	To assess treatment pattern with ranibizumab	From Baseline to Month 12

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 11, 2013
• Primary Completion (ACTUAL): September 14, 2016
• Study Completion (ACTUAL): September 14, 2016

Study Registration Dates

• First Submitted: August 12, 2013
• First Submitted That Met QC Criteria: August 13, 2013
• First Posted (ESTIMATE): August 14, 2013

Study Record Updates

• Last Update Posted (ACTUAL): June 24, 2019
• Last Update Submitted That Met QC Criteria: March 31, 2019
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Keywords: vision loss,PM,CNV,ranibizumab,verteporfinPDT,Brilliance
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Neoplasms; Eye Diseases; Neurologic Manifestations; Uveal Diseases; Neoplastic Processes; Choroid Diseases; Sensation Disorders; Refractive Errors; Metaplasia; Neoplasm Metastasis; Choroidal Neovascularization; Neovascularization, Pathologic; Myopia; Vision, Low; Vision Disorders; Physiological Effects of Drugs; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Photosensitizing Agents; Dermatologic Agents; Ranibizumab; Verteporfin
• Other Study ID Numbers: CRFB002F2302

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

IPD Plan Description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No